联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4246人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313681, encodeId=b647131368155, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究, objectType=article, longId=123846, objectId=166d123846a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=166d123846a2, replyNumber=0, likeNumber=54, createdTime=2017-12-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=166d123846a2, moduleTitle=Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=166d123846a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313680, encodeId=fc401313680c4, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, objectType=article, longId=123310, objectId=7e0a123310a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e0a123310a5, replyNumber=0, likeNumber=21, createdTime=2017-12-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e0a123310a5, moduleTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e0a123310a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313679, encodeId=5c9513136e92a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Liver Int：原位肝移植后，DAA药物联合治疗丙型肝炎复发患者，展示出良好的疗效且耐受性良好, objectType=article, longId=123103, objectId=43c5123103be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43c5123103be, replyNumber=0, likeNumber=59, createdTime=2017-12-13, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43c5123103be, moduleTitle=Liver Int：原位肝移植后，DAA药物联合治疗丙型肝炎复发患者，展示出良好的疗效且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43c5123103be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313678, encodeId=3c8213136e8fa, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者, objectType=article, longId=122934, objectId=8533122934c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8533122934c1, replyNumber=0, likeNumber=54, createdTime=2017-12-12, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8533122934c1, moduleTitle=【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8533122934c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313677, encodeId=630113136e7ab, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Viral Hepat：对阿德福韦单一治疗应答不佳，再使用以阿德福韦为基础的联合治疗后的有效性和安全性, objectType=article, longId=121517, objectId=0c5512151e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c5512151e84, replyNumber=0, likeNumber=65, createdTime=2017-11-28, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c5512151e84, moduleTitle=J Viral Hepat：对阿德福韦单一治疗应答不佳，再使用以阿德福韦为基础的联合治疗后的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c5512151e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313676, encodeId=d1f713136e6c1, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Blood：罗米地辛与普拉曲沙的联合治疗难治性/复发性T细胞淋巴瘤可获得高反应率。, objectType=article, longId=120438, objectId=26471204387a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26471204387a, replyNumber=0, likeNumber=64, createdTime=2017-11-18, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26471204387a, moduleTitle=Blood：罗米地辛与普拉曲沙的联合治疗难治性/复发性T细胞淋巴瘤可获得高反应率。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26471204387a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313675, encodeId=fb8913136e5b2, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=“引领治疗新思路，从单药到联合”——原创新药西达本胺纳入医保后开辟联合治疗新策略, objectType=article, longId=118516, objectId=56cf1185161e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56cf1185161e, replyNumber=0, likeNumber=52, createdTime=2017-11-04, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56cf1185161e, moduleTitle=“引领治疗新思路，从单药到联合”——原创新药西达本胺纳入医保后开辟联合治疗新策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56cf1185161e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313674, encodeId=ceca13136e4f6, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Thorac Oncol：案例—— 化疗和PD-1药物联合治疗导致的肺癌分型转化, objectType=article, longId=116752, objectId=383c116e52b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=383c116e52b9, replyNumber=0, likeNumber=109, createdTime=2017-10-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=383c116e52b9, moduleTitle=J Thorac Oncol：案例—— 化疗和PD-1药物联合治疗导致的肺癌分型转化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=383c116e52b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313673, encodeId=fcec13136e32d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=牙颌面畸形正畸正颌联合治疗, objectType=article, longId=113720, objectId=79b3113e200e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79b3113e200e, replyNumber=0, likeNumber=79, createdTime=2017-09-24, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79b3113e200e, moduleTitle=牙颌面畸形正畸正颌联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79b3113e200e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313672, encodeId=c26113136e234, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Periodontal Res：Er：YAG与Nd:YAG激光联合治疗慢性牙周炎, objectType=article, longId=112695, objectId=7545112695f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7545112695f2, replyNumber=0, likeNumber=61, createdTime=2017-09-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7545112695f2, moduleTitle=J Periodontal Res：Er：YAG与Nd:YAG激光联合治疗慢性牙周炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7545112695f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313671, encodeId=c5e613136e153, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究, objectType=article, longId=111056, objectId=508e111056bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=508e111056bc, replyNumber=0, likeNumber=56, createdTime=2017-08-29, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508e111056bc, moduleTitle=JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=508e111056bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313670, encodeId=d77213136e0ef, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Nature：一周后又一篇DNA损伤机制！癌症免疫联合治疗的希望, objectType=article, longId=107576, objectId=0cbc10e5763c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cbc10e5763c, replyNumber=0, likeNumber=103, createdTime=2017-08-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cbc10e5763c, moduleTitle=Nature：一周后又一篇DNA损伤机制！癌症免疫联合治疗的希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cbc10e5763c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313669, encodeId=a4d7131366919, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法, objectType=article, longId=107141, objectId=799310e141c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=799310e141c9, replyNumber=0, likeNumber=56, createdTime=2017-07-31, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=799310e141c9, moduleTitle=Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=799310e141c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313668, encodeId=b21b131366825, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Chest ：慢性阻塞性肺病患者GFF MDI联合治疗的效益与症状负荷之间的联系, objectType=article, longId=106440, objectId=d10910644012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d10910644012, replyNumber=0, likeNumber=107, createdTime=2017-07-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d10910644012, moduleTitle=Chest ：慢性阻塞性肺病患者GFF MDI联合治疗的效益与症状负荷之间的联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d10910644012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313667, encodeId=4a2c131366efc, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Eur Respir J：早期联合治疗降低肺动脉高压右心室容积！, objectType=article, longId=105079, objectId=c94a1050e951, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c94a1050e951, replyNumber=0, likeNumber=110, createdTime=2017-07-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c94a1050e951, moduleTitle=Eur Respir J：早期联合治疗降低肺动脉高压右心室容积！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c94a1050e951)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313666, encodeId=4dd31313666d4, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Blood：pomalidomide、bortezomib和dexamethasone联合治疗复发性多发性骨髓瘤的很大耐受剂量、疗效和安全性。, objectType=article, longId=104924, objectId=e6b910492475, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6b910492475, replyNumber=0, likeNumber=73, createdTime=2017-07-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6b910492475, moduleTitle=Blood：pomalidomide、bortezomib和dexamethasone联合治疗复发性多发性骨髓瘤的很大耐受剂量、疗效和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6b910492475)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313665, encodeId=965213136651f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者采用替格列汀与canagliflozin联合治疗的长期安全性和疗效！, objectType=article, longId=102438, objectId=598e102438d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=598e102438d5, replyNumber=0, likeNumber=58, createdTime=2017-06-21, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=598e102438d5, moduleTitle=Diabetes Obes Metab：2型糖尿病患者采用替格列汀与canagliflozin联合治疗的长期安全性和疗效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=598e102438d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313664, encodeId=5808131366416, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, objectType=article, longId=101423, objectId=a07f101423fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a07f101423fa, replyNumber=0, likeNumber=0, createdTime=2017-06-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a07f101423fa, moduleTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a07f101423fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313663, encodeId=42f21313663f0, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ADV FUNCT MATER：多功能纳米诊疗平台，双模态成像导航下的肿瘤联合治疗, objectType=article, longId=100206, objectId=71b610020698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71b610020698, replyNumber=0, likeNumber=65, createdTime=2017-06-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71b610020698, moduleTitle=ADV FUNCT MATER：多功能纳米诊疗平台，双模态成像导航下的肿瘤联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71b610020698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313662, encodeId=3c9313136624c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Adv Mater：黑磷纳米药物运输体系，多模式联合治疗癌症, objectType=article, longId=100047, objectId=92b410004e13, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92b410004e13, replyNumber=0, likeNumber=75, createdTime=2017-05-30, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92b410004e13, moduleTitle=Adv Mater：黑磷纳米药物运输体系，多模式联合治疗癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92b410004e13)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究

2017-12-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著

2017-12-15

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Liver Int：原位肝移植后，DAA药物联合治疗丙型肝炎复发患者，展示出良好的疗效且耐受性良好

2017-12-13

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者

2017-12-12

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Viral Hepat：对阿德福韦单一治疗应答不佳，再使用以阿德福韦为基础的联合治疗后的有效性和安全性

2017-11-28

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Blood：罗米地辛与普拉曲沙的联合治疗难治性/复发性T细胞淋巴瘤可获得高反应率。

2017-11-18

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

“引领治疗新思路，从单药到联合”——原创新药西达本胺纳入医保后开辟联合治疗新策略

2017-11-04

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Thorac Oncol：案例—— 化疗和PD-1药物联合治疗导致的肺癌分型转化

2017-10-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

牙颌面畸形正畸正颌联合治疗

2017-09-24

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Periodontal Res：Er：YAG与Nd:YAG激光联合治疗慢性牙周炎

2017-09-14

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究

2017-08-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Nature：一周后又一篇DNA损伤机制！癌症免疫联合治疗的希望

2017-08-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法

2017-07-31

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Chest ：慢性阻塞性肺病患者GFF MDI联合治疗的效益与症状负荷之间的联系

2017-07-25

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Eur Respir J：早期联合治疗降低肺动脉高压右心室容积！

2017-07-11

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Blood：pomalidomide、bortezomib和dexamethasone联合治疗复发性多发性骨髓瘤的很大耐受剂量、疗效和安全性。

2017-07-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Diabetes Obes Metab：2型糖尿病患者采用替格列汀与canagliflozin联合治疗的长期安全性和疗效！

2017-06-21

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？

2017-06-11

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ADV FUNCT MATER：多功能纳米诊疗平台，双模态成像导航下的肿瘤联合治疗

2017-06-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Adv Mater：黑磷纳米药物运输体系，多模式联合治疗癌症

2017-05-30

科室
- - 订阅+
  - 更多科室
工具
服务